期刊文献+

复方丹参滴丸对冠心病心绞痛MCP-1及IL-6的影响 被引量:3

Effect of Compound Danshen Dripping Pills on Patients with Coronary Heart Disease and Angina Pectoris MCP-1 and IL-6
下载PDF
导出
摘要 目的:探讨复方丹参滴丸对冠心病心绞痛患者血清单核细胞趋化蛋白-1(MCP-1)、白介素-6(IL-6)的影响。方法:选取笔者所在医院收治的180例冠心病心绞痛患者,采用随机数字表法将其分为治疗组与对照组,各90例。对照组给予常规内科治疗,治疗组在对照组治疗的基础上给予复方丹参滴丸治疗,疗程均为30 d。采用酶联免疫吸附法(ElISA)检测患者治疗前后血清MCP-1、IL-6浓度。结果:对照组治疗前后血清MCP-1、IL-6浓度比较差异无统计学意义(P>0.05)。治疗组治疗后血清MCP-1、IL-6浓度明显下降,与治疗前及治疗后对照组比较,差异有统计学意义(P<0.05)。结论:复方丹参滴丸可降低不稳定型心绞痛患者MCP-1、IL-6血清浓度,对冠心病心绞痛有良好的治疗作用。 Objective:To investigate the the effect of Compound Danshen Dripping Pills on serum in patients with coronary heart disease and angina pectoris of monocyte chemoattractant protein-1(MCP-1),interleukin-6 (IL-6). Method:Selecting the author’s hospital treated 180 cases of coronary heart disease angina pectoris patients,using the random number table method 180 cases were divided into treatment group and control group,90 cases in each. Control group was given conventional medical treatment,treatment group on the basis of control group treatment Compound Danshen Dropping Pills was given a course of 30 days. By using enzyme-linked immunosorbent(ElISA) before and after treatment in patients with serum concentration of MCP-1,IL-6.Result:The control group before and after treatment serum concentration of MCP-1,IL-6 had no statistically significant difference(P〉0.05). Treatment group after treatment serum concentration of MCP-1,IL-6 droped obviously,compared with control group before and after treatment,the differences were statistically significant(P〈0.05).Conclusion:Compound Danshen Dripping Pills can reduce MCP-1 in patients with unstable angina pectoris,serum IL-6 concentration,has a good therapeutic effect on angina pectoris of coronary heart disease.
出处 《中外医学研究》 2014年第16期10-11,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 复方丹参滴丸 冠心病 心绞痛 单核细胞趋化蛋白-1 白介素-6 Compound Danshen Dripping Pills Coronary heart disease Angina peetoris Monocyte ehemoattraetant protein-1 Interleukin-6
  • 相关文献

参考文献8

二级参考文献32

  • 1无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量:2053
  • 2戴瑞鸿.中西医结合治疗冠心病"谈医论药".中国医学论坛报,2008-5-29.
  • 3袁如生,李广平.复方丹参滴丸多靶点药理作用及对冠心病的防治.中国医学论坛报,2008-4-13.
  • 4Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis, 2003, 167(1):73-79.
  • 5Davis NE. Atherosclerosis-an inflammatory process[J].J Insur Med, 2005, 37(1):72-75.
  • 6Ridker PM. High-sensitivity C-reactive Protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease [J]. Circulation, 2001, 103(13): 1813-1818.
  • 7Guido S, Riceardo P, Marco R.et al. Association of plasma homocysteine with the number of major coronary severely narrowed [J].Am J Cardiol, 2001, 88(9):1027-1030.
  • 8罗玮.普伐他汀对血浆C-反应蛋白的长期作用.国外医学:心血管疾病分册,2002,(2):118-118.
  • 9Gensini G G. A more meaningful scoring system for deter- mining the severity of coronary heart disease [ J ]. Am J Cardiol, 1983, 51 (3) : 606.
  • 10Kopp H P, Kopp C W, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients [ J]. Artefioscler Thromb Vase Biol, 2003, 23 (6) : 1042- 1047.

共引文献39

同被引文献39

引证文献3

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部